FDA Approved VTAMA Cream for Treating Atopic Dermatitis in Adults, Children
Organon, the company behind VTAMA, received FDA approval ahead of its scheduled date of March 12, 2025.
The FDA approved Vtama (tapinarof) cream 1% for treating atopic dermatitis (AD) in adults and children as young as 2-years-old. This approval is the latest option for a skin condition that impacts millions, especially children and those of color.
Atopic dermatitis is a chronic skin condition that causes inflammation, itching and dryness and is more common in Black and Hispanic children, with Black children being 1.7 times more likely to develop it.
Organon, the company behind VTAMA, received FDA approval ahead of its scheduled date of March 12, 2025.
The FDA’s decision was based on studies called the ADORING trials, which tested VTAMA cream in patients aged two and older with moderate to severe AD. After 8 weeks, nearly half of the patients treated with VTAMA achieved clear or almost clear skin compared to only about 14% in the placebo group.
In addition, patients reported reductions in itching, a symptom that affects their quality of life.
Adelaide A. Hebert, M.D., a pediatric dermatologist and lead investigator for the ADORING program, highlighted the importance of these results.
“VTAMA cream has the potential to bring much-needed relief to children suffering from this disease,” Hebert said. “The reduction in itch is particularly meaningful for patients and their families.”
A follow-up study, ADORING 3, examined the long-term safety and effectiveness of VTAMA cream over 48 weeks.
Results showed that many patients could stop using the cream for about 80 days before symptoms returned. When symptoms did come back, reapplying the cream effectively cleared the skin again.
The safety profile remained consistent with earlier studies, confirming that VTAMA is safe for long-term use.
Beyond its immediate benefits, VTAMA’s approval is especially critical for communities that have historically been underrepresented in dermatology research.
Andrew F. Alexis, M.D., vice-chair for Diversity and Inclusion in Dermatology at Weill Cornell Medicine, said there’s a major gap in addressing the needs of patients with skin of color.
“Clinical trials often don’t reflect the diversity of the disease population.”
In addition to treating atopic dermatitis, VTAMA had earlier success in 2022 when it became the first non-steroidal topical treatment for plaque psoriasis in over 25 years.
With atopic dermatitis, it’s approved for use without restrictions on duration or the percentage of body surface area affected.
Breaking Down Health Plans, HSAs, AI With Paul Fronstin of EBRI
November 19th 2024Featured in this latest episode of Tuning In to the C-Suite podcast is Paul Fronstin, director of health benefits research at EBRI, who shed light on the evolving landscape of health benefits with editors of Managed Healthcare Executive.
Listen
Vaccination Not a Risk Factor for Pediatric-Onset MS, Study Finds
December 16th 2024Previous studies have found no association between vaccination and MS in adults. To evaluate the association between vaccinations and pediatric-onset MS, researchers conducted a retrospective case-control study using data from the Bavarian Association of Statutory Health Insurance Physicians database.
Read More
In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting Loren McCaghy, director of consulting, health and consumer engagement and product insight at Accenture, to discuss the organization's latest report on U.S. consumers switching healthcare providers and insurance payers.
Listen
